127 related articles for article (PubMed ID: 38159645)
1. Exploration of the optimal time to discontinue propranolol treatment in infantile hemangiomas: A prospective study.
Wang L; Wang W; Zhou Z; Li J; Li Z; Lv R; Xu G; Bi J; Huo R
J Am Acad Dermatol; 2024 Apr; 90(4):783-789. PubMed ID: 38159645
[TBL] [Abstract][Full Text] [Related]
2. Recurrence rate of infantile hemangioma after oral propranolol therapy.
Frongia G; Byeon JO; Mehrabi A; Günther P
Eur J Pediatr; 2021 Feb; 180(2):585-590. PubMed ID: 33188478
[TBL] [Abstract][Full Text] [Related]
3. Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment.
Kagami S; Kaneko M; Kishi A; Katori T
J Dermatol; 2018 Sep; 45(9):1109-1112. PubMed ID: 29952019
[TBL] [Abstract][Full Text] [Related]
4. Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol.
Meyer-Mueller C; Nicholson C; Polcari I; Boull C; Maguiness S
Pediatr Dermatol; 2022 Mar; 39(2):255-259. PubMed ID: 35178750
[TBL] [Abstract][Full Text] [Related]
5. Propranolol for infantile hemangiomas.
Bagazgoitia L; Torrelo A; Gutiérrez JC; Hernández-Martín A; Luna P; Gutiérrez M; Baño A; Tamariz A; Larralde M; Alvarez R; Pardo N; Baselga E
Pediatr Dermatol; 2011; 28(2):108-14. PubMed ID: 21385205
[TBL] [Abstract][Full Text] [Related]
6. Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence.
Xiao Q; Li Q; Zhang B; Yu W
Pediatr Surg Int; 2013 Jun; 29(6):575-81. PubMed ID: 23519547
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study.
Nagata E; Kashiwagura Y; Okada E; Tanaka S; Sano S; Nishida M; Hayano S; Iwashima S; Hakamata A; Odagiri K; Inui N; Watanabe H; Umemura K; Uchida S
J Pharmacol Sci; 2022 Jun; 149(2):60-65. PubMed ID: 35512856
[TBL] [Abstract][Full Text] [Related]
8. Treatment of infantile capillary hemangioma of the eyelid with systemic propranolol.
Vassallo P; Forte R; Di Mezza A; Magli A
Am J Ophthalmol; 2013 Jan; 155(1):165-170.e2. PubMed ID: 22967870
[TBL] [Abstract][Full Text] [Related]
9. Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age.
Gatts JE; Rush MC; Check JF; Samelak DM; McLean TW
Pediatr Dermatol; 2022 May; 39(3):389-393. PubMed ID: 35243678
[TBL] [Abstract][Full Text] [Related]
10. Effects of propranolol therapy in Moroccan children with infantile hemangioma.
Lahrichi A; Hali F; Baline K; Fatoiki FZE; Chiheb S; Khadir K
Arch Pediatr; 2018 Nov; 25(8):449-451. PubMed ID: 30361087
[TBL] [Abstract][Full Text] [Related]
11. Predictors of poor response to oral propranolol in infantile hemangiomas.
Hali F; Moubine I; Berrami H; Serhier Z; Othmani MB; Chiheb S
Arch Pediatr; 2023 Oct; 30(7):455-457. PubMed ID: 37394367
[TBL] [Abstract][Full Text] [Related]
12. Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas.
Hu L; Zhou B; Huang H; Chang L; Qiu Y; Ma G; Chen H; Jin Y; Xu X; Lin X; Li W
J Dermatol; 2016 Oct; 43(10):1160-1166. PubMed ID: 26945921
[TBL] [Abstract][Full Text] [Related]
13. Thirty-two Japanese cases of infantile hemangiomas treated with oral propranolol.
Kagami S; Kaneko M; Katori T
J Dermatol; 2018 Jun; 45(6):719-722. PubMed ID: 29603774
[TBL] [Abstract][Full Text] [Related]
14. Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience.
Georgountzou A; Karavitakis E; Klimentopoulou A; Xaidara A; Kakourou T
Acta Paediatr; 2012 Oct; 101(10):e469-74. PubMed ID: 22804809
[TBL] [Abstract][Full Text] [Related]
15. Multiple pulmonary infantile hemangiomas responsive to oral propranolol.
Galdeano F; Herón A; Moreno S; Aprea G; Meneses M; Torrelo A
Pediatr Dermatol; 2021 Jan; 38(1):226-228. PubMed ID: 33155718
[TBL] [Abstract][Full Text] [Related]
16. Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas.
Wang L; Li S; Gao Q; Lv R; Xu G; Li X; Bi J; Huo R
Head Neck; 2021 May; 43(5):1553-1562. PubMed ID: 33539620
[TBL] [Abstract][Full Text] [Related]
17. A novel topical nano-propranolol for treatment of infantile hemangiomas.
Chen ZG; Zheng JW; Yuan ML; Zhang L; Yuan WE
Nanomedicine; 2015 Jul; 11(5):1109-15. PubMed ID: 25791814
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma.
Aly MM; Hamza AF; Abdel Kader HM; Saafan HA; Ghazy MS; Ragab IA
Eur J Pediatr; 2015 Nov; 174(11):1503-9. PubMed ID: 25982338
[TBL] [Abstract][Full Text] [Related]
19. Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects.
Twist J; Chen A; Poffenberger P; Zinn Z
Pediatr Dermatol; 2022 Mar; 39(2):273-274. PubMed ID: 35178766
[TBL] [Abstract][Full Text] [Related]
20. Propranolol is more effective than pulsed dye laser and cryosurgery for infantile hemangiomas.
Kagami S; Kuwano Y; Shibata S; Uwajima Y; Yamada D; Miyamoto A; Miyagawa T; Araki M; Takahashi K; Isomura S; Aozasa N; Masui Y; Yamamoto M; Inuzuka R; Katori T; Sato S
Eur J Pediatr; 2013 Nov; 172(11):1521-6. PubMed ID: 23812512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
